PDL1 Expression and Outcomes in Histiocytic Neoplasms

Matthew J Moon1, Mohammed M Milhem2, John M Rieth2

  • 1Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

PubMed
Summary

Immune checkpoint inhibitors (ICIs) show promise as a first-line treatment for rare histiocytic neoplasms like histiocytic sarcoma (HS) and interdigitating dendritic cell sarcoma (IDCS). High PD-L1 expression may predict a strong response to these novel therapies.